Artivion, Inc. (NYSE:AORT) Stock Has Consensus Price Target of $39.00 According to Brokerages

Posted by Brenda Bartman on Nov 8th, 2026

Shares of Artivion, Inc. (NYSE:AORT – Get Free Report) have earned an average rating of “Moderate Buy” from the seven analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $39.00.

AORT has been the subject of a number of recent research reports. Citizens Jmp reduced their price target on Artivion from $48.00 to $42.00 and set a “market outperform” rating for the company in a research report on Friday. Wall Street Zen downgraded shares of Artivion from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Jefferies Financial Group assumed coverage on shares of Artivion in a research report on Tuesday, October 20th. They issued a “buy” rating and a $31.00 price objective on the stock. Canaccord Genuity Group reduced their target price on shares of Artivion from $40.00 to $30.00 and set a “buy” rating for the company in a report on Friday. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $44.00 target price on shares of Artivion in a research report on Monday, July 20th.

View Our Latest Research Report on Artivion

Insider Transactions at Artivion

In related news, CEO James P. Mackin sold 70,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the sale, the chief executive officer owned 877,275 shares in the company, valued at approximately $25,397,111.25. This represents a 7.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Jean F. Holloway sold 977 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total value of $27,834.73. Following the transaction, the senior vice president directly owned 184,118 shares of the company’s stock, valued at $5,245,521.82. This trade represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 90,460 shares of company stock worth $2,557,366 in the last three months. Insiders own 6.30% of the company’s stock.

Institutional Trading of Artivion

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Diversified Trust Co acquired a new stake in shares of Artivion in the third quarter valued at approximately $297,000. Aberdeen Group plc bought a new position in shares of Artivion during the 3rd quarter worth approximately $11,891,000. Allworth Financial LP increased its holdings in shares of Artivion by 2,048.3% during the 3rd quarter. Allworth Financial LP now owns 1,246 shares of the company’s stock worth $28,000 after acquiring an additional 1,188 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Artivion by 9.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 120,333 shares of the company’s stock worth $2,746,000 after acquiring an additional 10,426 shares during the last quarter. Finally, Maryland State Retirement & Pension System acquired a new position in shares of Artivion during the 3rd quarter worth approximately $245,000. 86.37% of the stock is owned by institutional investors.

Artivion Stock Down 20.1%

AORT stock opened at $20.23 on Friday. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.47 and a quick ratio of 2.51. The stock has a market capitalization of $986.66 million, a P/E ratio of -56.21 and a beta of 1.31. The business has a 50-day moving average of $23.55 and a 200-day moving average of $28.98. Artivion has a fifty-two week low of $19.16 and a fifty-two week high of $48.25.

Artivion (NYSE:AORT – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.14. Artivion had a positive return on equity of 5.11% and a negative net margin of 3.65%. The business had revenue of $123.79 million for the quarter, compared to analyst estimates of $120.97 million. On average, sell-side analysts anticipate that Artivion will post 0.37 earnings per share for the current fiscal year.

Artivion News Roundup

Here are the key news stories impacting Artivion this week:

Positive Sentiment: Q3 revenue rose 9% year over year to $123.8 million, exceeding analysts’ estimates of about $121 million. The company also reported non-GAAP EPS of $0.08, above a consensus estimate of a $0.06 loss cited in one report. Artivion Q3 results
Positive Sentiment: Artivion forecast 2026 revenue of $484 million to $492 million and said it is preparing to launch its NEXUS product in January 2027, offering potential future growth catalysts. Revenue outlook and NEXUS launch
Neutral Sentiment: Citizens JMP lowered its price target to $42 from $48 but maintained a Market Outperform rating; the revised target still implies substantial upside from the cited share price. Citizens JMP recommendations
Negative Sentiment: Canaccord also cut its target, to $30, adding to concerns about analysts’ reassessment of the stock’s outlook. Canaccord price-target change
Negative Sentiment: Despite revenue growth, Artivion posted a $7.9 million GAAP net loss, and adjusted EBITDA fell 8% to $22.5 million. Zacks also reported that the $0.08 quarterly EPS missed its $0.11 estimate, highlighting that earnings expectations vary by source and may weigh on sentiment. Zacks earnings analysis

Artivion Company Profile

(Get Free Report)

Artivion, Inc (NYSE: AORT) is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company’s products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care.